Viking Therapeutics stock jumps premarket on obesity-drug data
Viking Therapeutics climbed more than 35% in premarket trading after new data suggested patients on its experimental obesity drug VK2735 preserved much of their weight loss even after switching to less frequent dosing schedules.
Viking Therapeutics (VKTX) climbed more than 35% in premarket trading Tuesday after new data suggested patients using its experimental obesity drug VK2735 were able to preserve much of their weight loss even after moving to less frequent dosing schedules. The study evaluated patients who first completed an initial dosing period before shifting to a less frequent schedule, according to the source text.